Repligen Corporation RGEN
170.29 USD -2.38 (-1.38%)
Regular-session close
170.29 0.00 0.00%
After hours · Nov 19, 4:26 PM ET
168.94 Day range 178.85
100.99 52-week range 198.87
- YTD
- +3.92%
- 1 year
- +9.81%
News
seekingalpha.com Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
defenseworld.net 3,054 Shares in Repligen Corporation $RGEN Bought by Ethic Inc. Ethic Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund…
seekingalpha.com AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity During this quarter, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index as the market rewarded the quality characteristics our process emphasizes. We benefited most…
seekingalpha.com Alger Mid Cap 40 ETF Q3 2026 Portfolio Review Twist Bioscience Corp., Cloudflare Inc., and Repligen Corporation were among the top contributors to performance. We believe Cloudflare's extensive network and expanding product portfolio position it…
seekingalpha.com Voya Small Cap Growth Strategy Q3 2026 Contributors And Detractors For the quarter ended September 30, 2026, the Fund underperformed the Index on a NAV basis, due to stock selection. Negative stock selection in the industrials, financials, and materials sectors was…benzinga.com Repligen To Issue $1B Of 0.25% Convertible Senior Notes Due 2031 As Part Of Exchange, With ~$541.4M Of New Notes Issued In Exchange For ~$456.8M Of 2028 Notes And ~$458.6M Of New Notes Issued For Cash Repligen Corporation (NASDAQ:RGEN) ("Repligen"), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00%…
benzinga.com RBC Capital Maintains Outperform on Repligen, Raises Price Target to $200 RBC Capital analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $185 to $200.
benzinga.com Repligen Q3 2026 Earnings Call Transcript Repligen (NASDAQ:RGEN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Repligen Raises FY2026 Adj EPS Guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 Est; Raises FY2026 Sales Guidance from $813.000M-$835.000M to $844.000M-$852.000M vs $829.693M Est Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 analyst estimate. Raises FY2026 sales outlook from $813.000 million-$835.000 million to $844.000…
benzinga.com Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $180 Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:RGEN) with a Hold and raises the price target from $145 to $180.
